UCapital NewsBusiness Super App · news connected to data, companies, people and deals
IT
VoicesWire
LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
381
via finance.yahoo.comBusiness & Companies

PCPG Market to Reach US$670 Million by 2036 at 7.3% CAGR, Driven by Targeted Therapies

FROM THE WIRE · FINANCE.YAHOO.COM

Company Logo Up from about US$300 million in 2025 across the US, EU4, UK and Japan, as Merck's WELIREG, the first oral targeted PCPG therapy, faces pipeline rivals from Novartis, Jazz and Perspective. Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE) -- "Pheochromocytomas and…

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishGrowing PCPG market benefits pharmaceutical companies with therapies in this segment.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01PCPG market will grow from US$300 million in 2025 to US$670 million by 2036 across US, EU4, UK and Japan.
  2. 02Merck leads with WELIREG, the first oral targeted PCPG therapy, facing competition from Novartis, Jazz and Perspective.
  3. 03Radioligand and targeted therapies are transforming treatment of this rare endocrine disorder.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Merck & Co., Inc.MRKStock142.79 USDMarket closedtoday +0.60%Positive Novartis AGNVSStock143.28 USDMarket closedtoday +1.77%Positive Jazz Pharmaceuticals plcJAZZStock231.19 USDMarket closedtoday -0.09%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

UCapital News is the news section of UCapital24 S.p.A. All content is for information purposes only and does not constitute financial advice, a recommendation or a solicitation to invest. Even where terms such as “buy”, “sell”, “bullish” or “bearish”, or asset impact signals, appear, they only indicate the possible effect of a news item on the markets and are not an invitation to buy or sell financial instruments. News is analysed with UCapital AI and may also be published via API feeds from third-party providers, to give our users a continuous flow of news. UCapital24 S.p.A. accepts no liability of any kind for decisions made on the basis of this content. Wire releases are published by companies and are not verified by the newsroom.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.